SG/CALL/AMGEN/400/0.1/20.06.25 Stock

DE000SU6VTV2

Market Closed - Boerse Frankfurt Warrants 15:44:10 2024-05-31 EDT
0.91 ^EUR	+7.06%

1 month	+100.00%
3 months	+95.65%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart AMGEN INC.

Latest news about AMGEN INC.

Amgen : 2024 Annual Meeting of Stockholders Presentation	05-31	PU
US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment	05-28	RE
Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval	05-28	DJ
Weight-loss drug forecasts jump to $150 billion as supply grows	05-28	RE

More news

Quotes 5-day view

Date	Price	Change
24-05-31	0.9	+5.88%
24-05-30	0.85	+8.97%
24-05-29	0.78	-8.24%
24-05-28	0.85	-11.46%
24-05-27	0.96	-.--%

Real-time Boerse Frankfurt Warrants

Last update May 31, 2024 at 03:44 pm

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	AMGEN INC.
Issuer	Société Générale
WKN	SU6VTV
ISIN	DE000SU6VTV2
Date issued	2024-01-10
Strike	400 $
Maturity	2025-06-20 (384 Days)
Parity	10 : 1
Emission price	1.17 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	1.62 €
Lowest since issue	0.35 €
Spread	0.02 €
Spread %	2.11%

Company Profile

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.

Sector

More about the company